Replies to post #99196 on Anavex Life Sciences Corp (AVXL)

[scottsmith]

Add on a 500% premium for buyout and we are looking at over $400 per share!

[Amatuer17]

The o/s share count is 40 million plus only

So @ $100 - the market cap will be $4 Billion

For a ALZ drug that works - could generate billions of dollars of revenue with no other competitive drug in the near pipeline. Same thing is true for Rett and Parkinsons.

Further, looking at all signs, ALZ is not reversible so most likely the drug will be needed for lifetime - similar to Lipitor which generated approx $12B as yearly peak sales before patent expired.

So if A2-73 works in Alz (and Rett - Patkinsons) - it can generate revenue much higher than that.

So any BP will buy it at even $10 B plus which is $250 per share or more
(Pfizer bought Medivation for $14 B for one product with $2-3 B revenue)

If you want to dream - dream big. $250 per share from $6 sounds very nice to start the week